Phase 3 RCT in 180 adolescents with moderate-to-severe atopic dermatitis: stapokibart raised EASI 75 (73.9% vs 43%) and IGA response (57.1% vs 25%) vs placebo at week 18; adverse events were similar (62.5% vs 62%).
RCTn = 180
Zhou et al. Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicentre randomized double-blind placebo-controlled phase III trial